Avidity Biosciences shares are trading higher after Evercore ISI Group upgraded the stock from In-Line to Outperform and announced a $20 price target.
Portfolio Pulse from Benzinga Newsdesk
Avidity Biosciences' stock has been upgraded from In-Line to Outperform by Evercore ISI Group, with a new price target of $20.
May 22, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avidity Biosciences (RNA) receives an upgrade from Evercore ISI Group to Outperform and a $20 price target.
The upgrade from Evercore ISI Group is a positive signal for Avidity Biosciences (RNA), as it indicates increased confidence in the company's performance. The new price target of $20 suggests potential upside for the stock, which could attract more investors and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100